Spinraza Developer Disappointed with Canadian Agency’s Updated Recommendation

While the Canadian Association of Drugs and Technologies in Health (CADTH) recommended that the spinal muscular atrophy treatment Spinraza should be made available to a broader population of patients, it said public funding should not cover patients older than 12 — a determination that the treatment’s developer Biogen called…